<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Munoz-Garcia N</submitter><funding>INTERREG POCTEP Spain-Portugal</funding><funding>Fondo Europeo de Desarrollo Regional</funding><funding>Instituto de Salud Carlos III</funding><funding>Centro de Investigación Biomédica en Red de Cáncer</funding><pagination>408</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8773687</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(2)</volume><pubmed_abstract>Flow cytometric (FCM) analysis of the constant region 1 of the T-cell receptor β chain (TRBC1) expression for assessing Tαβ-cell clonality has been recently validated. However, its utility for the diagnosis of clonality of T-large granular lymphocytic leukemia (T-LGLL) needs to be confirmed, since more mature Tαβ cells (i.e., T-LGL normal-counterpart) show broader TRBC1+/TRBC1- ratios vs. total Tαβ cells. We compared the distribution and absolute counts of TRBC1+ and TRBC1- Tαβ-LGL in blood containing polyclonal (n = 25) vs. clonal (n = 29) LGL. Overall, polyclonal TRBC1+ or TRBC1- Tαβ-LGL ranged between 0.36 and 571 cells/μL (3.2-91% TRBC1+ cells), whereas the clonal LGL cases showed between 51 and 11,678 cells/μL (&lt;0.9% or >96% TRBC1+ cells). Among the distinct TCRVβ families, the CD28- effector-memory and terminal-effector polyclonal Tαβ cells ranged between 0 and 25 TRBC1+ or TRBC1- cells/μL and between 0 and 100% TRBC1+ cells, while clonal LGL ranged between 32 and 5515 TRBC1+ or TRBC1- cells/μL, representing &lt;1.6% or >98% TRBC1+ cells. Our data support the utility of the TRBC1-FCM assay for detecting T-cell clonality in expansions of Tαβ-LGL suspected of T-LGLL based on altered percentages of TRBC1+ Tαβ cells. However, in the absence of lymphocytosis or in the case of TαβCD4-LGL expansion, the detection of increased absolute cell counts by the TRBC1-FCM assay for more accurately defined subpopulations of Tαβ-LGL-expressing individual TCRVβ families, allows the detection of T-cell clonality, even in the absence of phenotypic aberrations.</pubmed_abstract><journal>Cancers</journal><pubmed_title>High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in Tαβ-Large Granular Lymphocytic Leukemia.</pubmed_title><pmcid>PMC8773687</pmcid><funding_grant_id>0639-IDIAL-NET-3-3</funding_grant_id><funding_grant_id>CB16/12/00400</funding_grant_id><funding_grant_id>EuroFlow</funding_grant_id><funding_grant_id>PI20-01346</funding_grant_id><funding_grant_id>IBPredoc17/00012</funding_grant_id><pubmed_authors>Mateos S</pubmed_authors><pubmed_authors>Moran-Plata FJ</pubmed_authors><pubmed_authors>van Dongen JJM</pubmed_authors><pubmed_authors>Lima M</pubmed_authors><pubmed_authors>Barrena S</pubmed_authors><pubmed_authors>Munoz-Garcia N</pubmed_authors><pubmed_authors>Villamor N</pubmed_authors><pubmed_authors>Almeida J</pubmed_authors><pubmed_authors>Orfao A</pubmed_authors><pubmed_authors>Caldas C</pubmed_authors></additional><is_claimable>false</is_claimable><name>High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in Tαβ-Large Granular Lymphocytic Leukemia.</name><description>Flow cytometric (FCM) analysis of the constant region 1 of the T-cell receptor β chain (TRBC1) expression for assessing Tαβ-cell clonality has been recently validated. However, its utility for the diagnosis of clonality of T-large granular lymphocytic leukemia (T-LGLL) needs to be confirmed, since more mature Tαβ cells (i.e., T-LGL normal-counterpart) show broader TRBC1+/TRBC1- ratios vs. total Tαβ cells. We compared the distribution and absolute counts of TRBC1+ and TRBC1- Tαβ-LGL in blood containing polyclonal (n = 25) vs. clonal (n = 29) LGL. Overall, polyclonal TRBC1+ or TRBC1- Tαβ-LGL ranged between 0.36 and 571 cells/μL (3.2-91% TRBC1+ cells), whereas the clonal LGL cases showed between 51 and 11,678 cells/μL (&lt;0.9% or >96% TRBC1+ cells). Among the distinct TCRVβ families, the CD28- effector-memory and terminal-effector polyclonal Tαβ cells ranged between 0 and 25 TRBC1+ or TRBC1- cells/μL and between 0 and 100% TRBC1+ cells, while clonal LGL ranged between 32 and 5515 TRBC1+ or TRBC1- cells/μL, representing &lt;1.6% or >98% TRBC1+ cells. Our data support the utility of the TRBC1-FCM assay for detecting T-cell clonality in expansions of Tαβ-LGL suspected of T-LGLL based on altered percentages of TRBC1+ Tαβ cells. However, in the absence of lymphocytosis or in the case of TαβCD4-LGL expansion, the detection of increased absolute cell counts by the TRBC1-FCM assay for more accurately defined subpopulations of Tαβ-LGL-expressing individual TCRVβ families, allows the detection of T-cell clonality, even in the absence of phenotypic aberrations.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2024-02-15T07:27:10.983Z</modification><creation>2022-02-11T16:04:53.126Z</creation></dates><accession>S-EPMC8773687</accession><cross_references><pubmed>35053571</pubmed><doi>10.3390/cancers14020408</doi></cross_references></HashMap>